Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lacto
| Current Price | ₹754.80 |
|---|---|
| Market Cap | ₹0 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Life Sciences Tools and Services; Life Sciences Tools and Services |
| P/E Ratio | 72.4 |
| 52-Week Range | ₹579.15 – ₹873.50 |
| Dividend Yield | 0.26% |
1. Contract Research Development & Manufacturing Services (CRDMO)-83.4% 2. Speciality Ingredients-16.6%
Anthem Biosciences Limited is trading at ₹754.80, with a market capitalisation of ₹0 Cr.
Anthem Biosciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Life Sciences Tools and Services; Life Sciences Tools and Services).
Anthem Biosciences Limited has a P/E of 72.4.